Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Wierda

Showing results (171-180 of 181) with videos related to

Pageof 19
Sort By:
Blood Cancer Journal|October 22, 2024
The DLEU2/miR-15a/miR-16-1 cluster shapes the immune microenvironment of chronic lymphocytic leukemiaRonghua Zhang, Priyanka Khare, Priyanka Banerjee, et al.
American Journal of Hematology|October 20, 2017
Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphomaYasmin Abaza, Hagop M Kantarjian, Stefan Faderl, et al.
Cancer|June 14, 2017
TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimensRashmi Kanagal-Shamanna, Preetesh Jain, Koichi Takahashi, et al.
American Journal of Hematology|March 15, 2020
Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemiaKoji Sasaki, Hagop Kantarjian, William Wierda, et al.
The New England Journal of Medicine|May 30, 2019
Ibrutinib and Venetoclax for First-Line Treatment of CLLNitin Jain, Michael Keating, Philip Thompson, et al.
Cancer Cell|September 22, 2023
ZNF683 marks a CD8<sup>+</sup> T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndromeErin M Parry, Camilla K Lemvigh, Stephanie Deng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2024
Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective StudyAdam S Kittai, David Bond, Ying Huang, et al.
Cancer|November 25, 2024
Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemiaWei-Ying Jen, Jennifer Marvin-Peek, Hagop M Kantarjian, et al.
Human Gene Therapy|April 30, 2014
Gene therapy: charting a future course--summary of a National Institutes of Health Workshop, April 12, 2013Marina O'Reilly, Howard J Federoff, Yuman Fong, et al.
The Journal of Clinical Investigation|August 3, 2016
Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cellsPartow Kebriaei, Harjeet Singh, M Helen Huls, et al.
Pageof 19

Showing results (171-180 of 181) with videos related to

Sort By:
Pageof 19
Blood Cancer Journal|October 22, 2024
The DLEU2/miR-15a/miR-16-1 cluster shapes the immune microenvironment of chronic lymphocytic leukemiaRonghua Zhang, Priyanka Khare, Priyanka Banerjee, et al.
American Journal of Hematology|October 20, 2017
Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphomaYasmin Abaza, Hagop M Kantarjian, Stefan Faderl, et al.
Cancer|June 14, 2017
TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimensRashmi Kanagal-Shamanna, Preetesh Jain, Koichi Takahashi, et al.
American Journal of Hematology|March 15, 2020
Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemiaKoji Sasaki, Hagop Kantarjian, William Wierda, et al.
The New England Journal of Medicine|May 30, 2019
Ibrutinib and Venetoclax for First-Line Treatment of CLLNitin Jain, Michael Keating, Philip Thompson, et al.
Cancer Cell|September 22, 2023
ZNF683 marks a CD8<sup>+</sup> T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndromeErin M Parry, Camilla K Lemvigh, Stephanie Deng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2024
Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective StudyAdam S Kittai, David Bond, Ying Huang, et al.
Cancer|November 25, 2024
Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemiaWei-Ying Jen, Jennifer Marvin-Peek, Hagop M Kantarjian, et al.
Human Gene Therapy|April 30, 2014
Gene therapy: charting a future course--summary of a National Institutes of Health Workshop, April 12, 2013Marina O'Reilly, Howard J Federoff, Yuman Fong, et al.
The Journal of Clinical Investigation|August 3, 2016
Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cellsPartow Kebriaei, Harjeet Singh, M Helen Huls, et al.
Pageof 19